PACIFIC 2
PACIFIC-2: Final Analysis of Concurrent Durvalumab + CRT Followed by Consolidation Durvalumab for Unresectable Stage III NSCLC

Released: April 29, 2024

Expiration: April 28, 2025

Activity

Progress
1
Course Completed